MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Kodu・Aktsiate loetelu・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Suletud

SektorTervishoid

14.36 0.28

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.31

Max

14.36

Põhinäitajad
By Trading Economics
Sissetulek	42M 17M
Müük	14M 169M
Kasumimarginaal	10.237
Töötajad	499
EBITDA	54M 48M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-0.21% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	18. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	2.1B 4.4B
Eelmine avamishind	14.08
Eelmine sulgemishind	14.36

Uudiste sentiment

By Acuity

84%

16%

340 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

5.925 / 7.38 Toetus ja vastupanu

Amicus Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2025, 14:38 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Nike, Oracle, FedEx, Sony -- WSJ

Võrdlus sarnastega

Hinnamuutus

Amicus Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.21% langus

12 kuu keskmine prognoos

Keskmine 14.25 USD -0.21%

Kõrge 19 USD

Madal 11 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Amicus Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Amicus Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.925 / 7.38Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

340 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.